| INTRODUC TI ON
Two major principles for coagulation factor replacement have been adopted in the clinical management of surgical procedures in patients with bleeding disorders such as haemophilia, either repetitive bolus injections (BI) every 6-12 hours or continuous infusion (CI) using a pump delivery system.
Continuous infusion was first introduced in the 1950s by
Brinkhous at the Haemophilia Centre at Chapel Hill. 1 It has been used by some haemophilia treaters for decades. It is favoured by many as it provides a safe and constant level of the deficient clotting factor by balancing input with clearance thereby reducing or eliminating the risk of early or late bleeding and dangerous peaks that may lead to a thrombotic event. CI may also be cost effective as it avoids the troughs and peaks associated with BI. 2 In contrast, BI need to be administered every 6-12 hours and there is a certain amount of product wastage as in order to provide adequate haemostasis the trough level needs to be above a certain level. This leads to increased costs compared to CI. 3 Indications for CI are maintenance of an efficient haemostatic coagulation factor level for a prolonged period (>3 days) in association with major bleeds and major and minor surgical procedures.
However, there are some concerns with the use of CI of coagulation factor concentrates. Bacterial growth in the infusion bag with the risk of infection and/or degradation of the coagulation factor concentrate during storage at room temperature are of particular importance. Phlebitis at the infusion site has regularly been reported using continuous infusion, but this can be easily avoided by adding small amounts of heparin to the infusion bag (5 U/mL).
Previously, a quite frequently reported complication was related to loss of battery power or other failures of the delivery pump system; however, this is very seldom reported nowadays due to new generation of infusion pumps. Finally, suspicion has been raised that CI may be associated with development of inhibitors, especially in non-severe haemophilia (although medical evidence in standard terms is lacking).
In a study comparing bolus injections (18 procedures) with continuous infusion (25 procedures) in 43 major surgical procedures performed in 40 severe haemophilia A patients, Batorova and
Martinowitz found improved safety of CI over BI. Higher trough levels were found in the CI group (0.44 ± 0.06 vs 0.31 ± 0.09 IU/ mL, P < 0.01) with a lower incidence of dangerous drops below 0.3 IU/mL (8% vs 44% of patients, respectively; P < 0.01) and a lower requirement for blood transfusions (12% vs 39%, P < 0.01).
Three of 18 patients in the BI group (17%) developed major bleeding complications compared to none in the CI group. Factor VIII dosage was lower by 36% in the CI group (467 ± 104 vs 733 ± 126 IU/kg; P < 0.01). 4 In a cross-sectional study of the current practices in Europe regarding continuous infusion and the inhibitor incidence following Clinical studies show that simoctocog alfa is highly effective in the treatment and prevention of bleeding episodes in previously treated adults and children, including those undergoing surgery.
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A recent analysis with pooled data from seven clinical studies examined the safety and efficacy of simoctocog alfa in surgical
prophylaxis. The analysis comprised data from 36 patients (both adults and children) with severe haemophilia A, who underwent 60 surgical procedures (28 major and 32 minor) and were administered simoctocog alfa as BI for bleeding prophylaxis. Efficacy was evaluated in 52 procedures and was rated as excellent or good in all but one surgery. There was no serious treatment-related adverse events and none of the patients developed inhibitors to FVIII.
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Our aim was to investigate the use of simoctocog alfa delivered by CI for major surgery in haemophilia A patients.
| MATERIAL S AND ME THODS
We investigated the use of CI of simoctocog alfa in haemo- Haemoglobin levels were also measured prior to surgery and daily in the postoperative phase until the patients were discharged from hospital.
The maintenance dose of CI was adjusted according to clearance recalculated daily according to actual control of FVIII levels using the formula: Clearance (mL/kg/h) = infusion rate (IU/kg/h)/measured factor level (IU/mL). 12 Testing for inhibitors to FVIII was performed on consecutive follow-up visits using the Nijmegen-Bethesda assay.
Concomitant treatment with tranexamic acid 25 mg/kg was
given four times daily. No pharmacological thromboprophylaxis was used. The study was approved by the local data protection supervisor.
| RE SULTS
A total of 24 major surgical procedures were performed in 17 patients. Twenty-two were orthopaedic surgeries, out of them four were ankle arthrodeses, six were knee arthroplasties, three were hip arthroplasties, three were osteosynthesis removals and six were other orthopaedic interventions. Patients' ages ranged from 
| Safety
No adverse events related to simoctocog alfa were observed, and no patients developed an inhibitor to the factor concentrate.
| Stability
Simoctocog alfa was dissolved to a concentration of 200 IU/mL and was found to be stable for 3 days both when measured by a onestage clotting assay based method and chromogenic assay ( Table 2 ).
| D ISCUSS I ON
Our study shows that the effects of CI with simoctocog alfa in 17 patients undergoing 24 surgeries procedures were excellent or good in all cases. The results reflect the results obtained in the GENA studies in which the efficacy of BI was rated as excellent or good in all but one procedure. 11 In our study, no patients developed an inhibitor to simoctocog alfa. The use of CI has raised concerns about the association of CI with an increased risk of development of inhibitors to FVIII. There have been conflicting results in the literature.
F I G U R E 1 Continuous infusion of simoctocog alfa in a patient with moderate haemophilia A undergoing ankle arthrodesis
A number of inhibitor cases have been described following CI with the majority being patients with moderate or mild haemophilia who were treated intensively for surgery and major bleeds. [13] [14] [15] Patients with mild or moderate haemophilia given CI often have low exposure rates to coagulation factor concentrates. In our study, the majority of patients had severe haemophilia A, and they had a higher number of exposure days than those with mild or moderate disease. This is borne out in a large retrospective survey on inhibitor development in European haemophilia centres using CI. A total of 742 haemophilia
A patients who underwent 1079 CI treatments were included. by our study. This is in contrast to previous small case series suggesting that CI may promote inhibitor development.
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However, CI should be used with caution in patients <20 exposure days as studies have shown that the risk of inhibitor development is increased in patients with <20 exposure days 16 and in mild/ moderate haemophilia A patients with high-risk mutations.
Continuous infusion may reduce treatment cost compared to bolus injections, since unnecessary peaks of the coagulation factor level are avoided. Several studies have shown that coagulation factor concentrate consumption may be reduced by CI compared to repetitive BI. The area under the curve (AUC) is two-thirds of the use of BI. 17 We found that the mean coagulation factor consumption in major surgery was 29 750 IU during the first 9 days. Due to differences in patient populations it is difficult to compare factor concentrate consumption between different studies, however an interesting observation is that simoctocog alfa administered as CI in our study, showed a 46% lower consumption of factor concentrate vs what was reported in the GENA surgical studies were repetitive simoctocog alfa BI were given (320 IU/kg vs 591 IU/kg). 11 In a prospective study conducted by Batorova et al, 4 where the patient populations were comparable with regards the age and severity of haemophilia, a 36% difference in factor consumption was reported when comparing CI vs BI. In our study, we adjusted the infusion rate to reach a FVIII level of 70% during days 0-3, 50% for days 4-6, and 30% for days 7 and beyond. We believe that this approach is necessary to reduce the need for erythrocyte transfusions and avoid the use of pharmacological thromboprophylaxis following surgical procedures.
There was no evidence of risk of infection from our study. To avoid any risk of infection during CI, preparation and filling of the container must be performed under sterile conditions. Bacterial growth in cultures from mini-pump reservoirs and infusion sets appear not to be a problem within 72 hours. Extensive studies have
shown that FVIII and FIX concentrates are poor growth mediums for the majority of bacterial strains. 4, 18, 19 Most concentrates are stable after reconstitution at room temperature. We found that simoctocog alfa was stable for 3 days at room temperature. Stability studies performed in the early 1990s
showed that most concentrates were stable after reconstitution at room temperature for 3 days or more. 18 The newer recombinant products have shown extended stability over 24-48 hours.
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However, for safety reasons it is advisable to test the stability of each concentrate intended for use with the particular infusion set to be used.
None of our surgeries was associated with adverse events.
Previously phlebitis at the infusion site was often reported, most likely due to high osmolality of undiluted coagulation factor concentrate. In a meta-analysis of CI publications from 1992 to 2004
Hermans et al 25 observed this complication in 10.5%. Currently, phlebitis at the infusion site is very seldom seen after addition of small amounts of heparin (5 U/mL) in the infusion bag or parallel infusion of saline. 17, 26, 27 This practice is well documented in a study in Europe 5 and in other series. 28, 29 We added small amounts of heparin (5 U/mL) to the infusion bag, and no sign of phlebitis was observed.
Pump failure leading to an unexpected and dangerous drop in coagulation factor level are very seldom reported due to increased quality of pumps used in current practice. 12 There were no incidences of pump failure in our study.
| CON CLUS ION
Continuous infusion with simoctocog alfa was found to achieve excellent haemostatic efficacy in the majority of surgeries. No adverse events occurred and no inhibitors developed.
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